The probiotic strain Escherichia coli Nissle 1917 prevents papain-induced respiratory barrier injury and severe allergic inflammation in mice

Thomas Secher (1) , Isabelle Maillet (2) , Claire Mackowiak (2) , Jessica Le Bérichel (2) , Amandine Philippeau (2) , Corinne Panek (2) , Michèle Boury (3) , Eric Oswald (3, 1) , Abdelhadi Saoudi (3) , François Erard (2) , Marc Le Bert (2) , Valérie Quesniaux (2) , Aurélie Couturier-Maillard (2) , Bernhard Ryffel (2)

1 IRSD - Institut de Recherche en Santé Digestive
2 INEM - Immunologie et Neurogénétique Expérimentales et Moléculaires
3 CPTP - Centre de Physiopathologie Toulouse Purpan

Allergic asthma is characterized by a strong Th2 and Th17 response with inflammatory cell recruitment, airways hyperreactivity and structural changes in the lung. The protease allergen papain disrupts the airway epithelium triggering a rapid eosinophilic inflammation by innate lymphoid cell type 2 (ILC2) activation, leading to a Th2 immune response. Here we asked whether the daily oral administrations of the probiotic Escherichia coli strain Nissle 1917 (ECN) might affect the outcome of the papain protease induced allergic lung inflammation in BL6 mice. We find that ECN gavage significantly prevented the severe allergic response induced by repeated papain challenges and reduced lung inflammatory cell recruitment, Th2 and Th17 response and respiratory epithelial barrier disruption with emphysema and airway hyperreactivity. In conclusion, ECN administration attenuated severe protease induced allergic inflammation, which may be beneficial to prevent allergic asthma.

Domains: Life Sciences [q-bio]

Thomas Secher, Isabelle Maillet, Claire Mackowiak, Jessica Le Bérichel, Amandine Philippeau, et al.. The probiotic strain Escherichia coli Nissle 1917 prevents papain-induced respiratory barrier injury and severe allergic inflammation in mice. Scientific Reports, 2018, 8 (1), ⟨10.1038/s41598-018-29689-9⟩. ⟨hal-02126575⟩